| Literature DB >> 30909393 |
Daniel Pinos1, María Martínez-Solís2, Salvador Herrero3, Juan Ferré4, Patricia Hernández-Martínez5.
Abstract
ABC proteins are primary-active transporters that require the binding and hydrolysis of ATP to transport substrates across the membrane. Since the first report of an ABCC2 transporter as receptor of Cry1A toxins, the number of ABC transporters known to be involved in the mode of action of Cry toxins has increased. In Spodoptera exigua, a mutation in the SeABCC2 gene is described as genetically linked to resistance to the Bt-product XentariTM. This mutation affects an intracellular domain involved in ATP binding, but not the extracellular loops. We analyzed whether this mutation affects the role of the SeABCC2 as a functional receptor to Cry1A toxins. The results show that Sf21 cells expressing the truncated form of the transporter were susceptible to Cry1A toxins. Moreover, specific Cry1Ac binding was observed in those cells expressing the truncated SeABCC2. Additionally, no differences in the irreversible Cry1Ac binding component (associated with the toxin insertion into the membrane) were observed when tested in Sf21 cells expressing either the full-length or the truncated form of the SeABCC2 transporter. Therefore, our results point out that the partial lack of the nucleotide binding domain II in the truncated transporter does not affect its functionality as a Cry1A receptor.Entities:
Keywords: Bt resistance; Sf21 cells; heterologous expression; mode of action; truncated transporter
Mesh:
Substances:
Year: 2019 PMID: 30909393 PMCID: PMC6468857 DOI: 10.3390/toxins11030172
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1Predicted structure and expression analysis of the truncated SeABCC2. (a) Schematic illustration of the 3D structure of SeABCC2-FRA predicted using Phyre2 (http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index) with reference to the 3D structure of atp-binding cassette sub-family C member 8 isoform X2. (b) 2-D schematic structure of the truncated SeABCC2 showing the ECL and NBD regions. The 1121–1199 amino acid deletion in the NBDII is shown in orange, and amino acid positions that differ in both proteins are shown in red. (c) Immunostaining of the SeABCC2-XenR transporter expressed in Sf21 cells. Cells were stained with an anti-FLAG tag antibody followed by anti-mouse IgG conjugated to Alexa Fluor 488 (green signal). Cell nuclei were stained with DAPI (blue signal). Scale bar represents 20 µm.
Figure 2Effect of Cry1A proteins on the viability of Sf21 cells. Assays were performed using increasing concentrations of: Cry1Aa (a); Cry1Ab (b); and Cry1Ac (c). Assays were carried out for 3 h with Sf21 cells (circles) and Sf21-XenR cells (squares). Each value represents the mean of at least three independent assays (± SEM). Means were compared by two-way ANOVA, followed by Bonferroni’s comparison test.
Figure 3Binding of 125I-Cry1Ac to Sf21 cells expressing the SeABCC2-XenR. (a) Specific binding of 125ICry1Ac at increasing concentrations of Sf21 (blue) and Sf21-XenR (green) cells. Each bar represents the mean of at least three independent experiments (± SEM). Means were compared by two-way ANOVA, followed by Bonferroni’s comparison test (p <0.001). Significant differences between both cell lines are indicated by asterisks. (b) Competition binding assays with 125I-Cry1Ac using Sf21-XenR cells. Curves represent total binding of labeled Cry1Ac protein to increasing concentrations of unlabeled Cry1Aa (open triangles), Cry1Ab (full circles), and Cry1Ac (squares) as competitors. Each competition experiment was replicated at least three times and the error bars represent the standard error of the mean.
Figure 4Dissection of total Cry1Ac binding into the non-specific and the specific binding (reversible and irreversible components) in Sf21 cells expressing the full-length (Sf21-FRA) or the truncated form (Sf21-XenR) of the SeABCC2 transporter.